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Abstract
Freeze-dried recombinant adeno-associated virus (rAAV) coated structural allografts have emerged
as an approach to engender necrotic cortical bone with host factors that will persist for weeks
following surgery to facilitate revascularization, osteointegration, and remodeling. However, one
major limitation is the nonporous cortical surface that prohibits uniform distribution of the rAAV
coating prior to freeze-drying. To overcome this we have developed a demineralization method to
increase surface absorbance while retaining the structural integrity of the allograft. Demineralized
bone wafers (DBW) made from human femoral allograft rings demonstrated a significant 21.1 %
(73.6 ± 3.9 % vs. 52.5 ± 2.6 %; p<0.001) increase in percent surface area coating versus mineralized
controls. Co-incubation of rAAV-luciferase (rAAV-Luc) coated DBW with a monolayer of
C3H10T1/2 cells in culture led to peak luciferase levels that were not significantly different from
soluble rAAV-Luc controls (p>0.05), although the peaks occurred at 60hrs and 12hrs, respectively.
To assess the transduction efficiency of rAAV-Luc coated DBW in vivo, we first performed a dose
response with allografts containing 107, 109 or 1010 particles that were surgically implanted into the
quadriceps of mice, and assayed by in vivo bioluminescence imaging (BLI) on days 1, 3, 5, 7, 10,
14, and 21. The results demonstrated a dose response in which the DBW coated with 1010 rAAV-
Luc particles achieved peak gene expression levels on day 3, which persisted until day 21, and was
significantly greater than the 107 dose throughout this time period (p<0.01). A direct comparison of
mineralized versus DBW coated with 1010 rAAV-Luc particles failed to demonstrate any significant
differences in transduction kinetics or efficiency in vivo. Thus, surface demineralization of human
cortical bone allograft increase its absorbance for uniform rAAV coating, without affecting vector
transduction efficiency.
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Introduction
Although massive allografts are widely used during reconstructive surgery of critical defects
in long bones, their limited osteogenic and remodeling potential is directly associated with the
25% to 35% failure rate within 3-years due to fracture and nonunion [1,2]. For those massive
allografts that survive, the failure rate at 10-years has been documented to be as high as 60%
[3-5]. The fractures at this late stage are the result of the accumulation of microcracks that
cannot be repaired by the necrotic bone. As a result of this poor clinical success, the use of
structural allografts has been restricted to repair segmental defects following tumor resection
in cancer patients in an attempt to salvage the limb and eliminate the need for prostheses. To
the end of a revitalizing structural allograft, we have developed a combination gene therapy-
tissue engineering approach that introduces angiogenic, osteoclastogenic and osteogenic
signals on the cortical surface via immobilized recombinant adeno-associate virus (rAAV)
[6,7]. The utility of this rAAV-coating approach has subsequently been realized for soft tissue
allografts [8] and stents [9], and the subject has been reviewed [10,11].
Despite the aforementioned problems with massive allograft, and concerns regarding
transmission of infectious agents [12,13], cortical allografts have remain the most popular
biomaterial used for limb sparing reconstructive surgery due to their biocompatibility and
biomechanical properties that have yet to be matched by synthetic biomaterials [14]. However,
one major limitation of cortical allograft as a biomaterial is its poor porosity, which
compromises its ability to be uniformly and reproducibly coated with therapeutic molecules.
In efforts to overcome these shortcomings, investigators have evaluated partially demineralized
cortical bone coated with hydrophilic coatings including biodegradable foams of
polycaprolactone (PCL), poly(propylene fumarate) (PPF) and poly(d,l-lactic-co glycolic acid)
(PLGA) with some success [15-17]. In our studies of rAAV-coated allografts, in which a
sorbitol solution of the vector is directly applied to the cortical surface, we have consistently
found that gravitational pooling of the vector prior to freeze-drying leads to nonuniform
distribution [6]. As a consequence, the in vivo gene therapy induced bone formation is
asymmetric and in most cases limited to one side of the allograft [7]. Thus, if the results of new
bone formation and connectivity with the host are to be improved, we must develop an approach
that increases the surface distribution of the rAAV coating by increasing surface absorption,
without decrease transduction efficiency. To this end, we investigated the effects of acid surface
demineralization of human femur cortical allografts on the release and transduction efficiency
of rAAV coatings.
Materials and methods
Preparation of mineralized and surface demineralized cortical bone graft wafers
Human cadaver femurs, previously debrieded and soaked in gentamycin solution, were cut into
cross-sectional rings ~5mm in width. Surface demineralization of the cortical bone was
performed by the Musculoskeletal Transplant Foundation and achieved by tween/trinton
treatment for 30 minutes, soaked in H2O2 for 15 minutes, sonicated in purified H2O for 5
minutes, air dried for 15 minutes, soaked in HCl for 5 minutes, sonicated 3 times in purified
H2O for 15 minutes each, and finally soaked in EtOH for 60 min. Acid penetration depth was
determined to be 30-80 microns. Experimental bone wafers were prepared from both
mineralized and surface demineralized cortical bone rings by cutting them into 10mm X 5mm
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X 3mm samples using a diamond saw as we have previously described [18]. The wafers were
sterilized under UV light prior to their use in vitro and in vivo experiments.
Preparation of rAAV-Luc
The rAAV vector expressing the firefly luciferase gene (rAAV-Luc) was purchased from the
Gene Core Facility of the University of North Carolina, Chapel Hill, North Carolina, USA.
The vector was prepared using the help virus free transfection method [19], and the titter of
purified stock was determined to be 1012 particles/ml.
Coating of cortical bone grafts
An aliquot of the rAAV-Luc stock solution containing 107,109 or 1010 particles of was
suspended in 20 μl of a 1% sorbitol-PBS solution, and directly pipetted onto the cortical surface
of bone grafts. The coated wafers were frozen on dry-ice and placed at −80 °C for 1 hour before
lyophilization as we have previously described [6]. Then the rAAV-Luc freeze-dried coated
wafers were stored at −80 °C until they were used.
Scanning electron microscopy (SEM) imaging of mineralized and surface demineralized
bone wafers
Both coated and uncoated, non-demineralized bone (NDB) wafers and demineralized bone
wafers (DBW) were mounted on a stainless steel stage with conductive tape and a drop of
conductive graphite adhesive was used to provide a pathway for electrons from the conductive
tape to the nonconductive bone grafts. All samples were freeze-dried and sputter coated to
apply a thin and completely continuous layer (~10 nm) of gold. A LEO 982 FE-SEM was then
used with an accelerating voltage of 10KV to view the surface microarchitecture of the grafts.
To analyze the coating of the bone grafts and surface microarchitecture, micrographs were
taken 9X and 3000X magnification of the specimens.
Quantification of surface coating on cortical bone wafers
30μl of a 1% sorbitol solution of PBS with red food coloring was pipetted onto NDB or DBW
(n=4), and freeze-dried. A digital photograph was taken of the wafers and the % surface coating
was quantified using NIH Image by manually tracing and dividing the red surface area by the
total wafer surface area.
In-vitro rAAV-Luc transduction assays
C3H10T1/2 cells (105 per well in 12-well plates) were grown to confluence in BME
supplemented with 2mM L-glutamine, 100units/ml penicillin, 100units/ml streptomycin, and
10%FCS (Hyclone, Logan, UT). To characterize rAAV-Luc transduction with DBW, four
groups of C3H10T1/2 monolayers were studied: Group1 untreated cells; Group2 cells
incubated with soluble rAAV-Luc only; Group 3 cells incubated with soluble rAAV-Luc in
the presence of DBW; and Group 4 cell incubated with rAAV-Luc coated DBW. After 12hr,
24hr, 36hr, 48hr, 60hr, or 72hr of culture at 37 °C, the cells were harvested and assayed for
firefly luciferase activity using the Dual-Luciferase Reporter Assay System (Promega, Cat. #
E1980) and a single-sample luminometer as we have previously described [8].
In-vivo rAAV-Luc transduction assays
The transduction efficiency of rAAV-Luc coated NDB and DBW in vivo was determined via
longitudinal bioluminescent imaging (BLI) as previously described [20,21]. All animal studies
were conducted in accordance with principles and procedures approved by the University of
Rochester Committee for Animal Resources. Surgeries were performed using an aseptic
technique. 8-week-old female or male C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME)
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were anesthetized, an 8- to 10-mm-vertical incision was made on the right leg, and quadriceps
femoris muscle was exposed. A small pocket was created at the top of the quadriceps femoris
muscle by blunt dissection for transplantation of rAAV-Luc coated wafers. The skin was closed
with 4-0 silk suture, and the mice were allowed to move freely after recovery from anesthesia.
BLI was performed on days 1, 3, 5, 7, 10, 14, 21, and 28 following intraperitoneal injection of
D-luciferin potassium salt (Xenogen, Cranbury, NJ) in an IVIS 100 Bioluminescence Imaging
System (Xenogen, Cranbury, NJ) as we have described previously [8]. Measurements of the
total integrated light signal (photons emitted/cm2/s) emitted from a standardized region of
interest in a standard time interval (5-minute exposure) was computed with the Living Image
software (Xenogen, Cranbury, NJ), and the BLI images were generated by overlaying the
bioluminescent light intensity map on a reflective-light photograph of the mouse.
Statistical analysis
All values are presented as mean ± SD. Statistical significance was determined using a two-
sided t-test for two group comparisons, or two-way ANOVA with Bonferroni post-hoc tests
for multiple group comparisons, where p<0.05 was considered to be significant.
Results
Effects of acid demineralization on cortical allograft bone morphology and surface coating
properties
To assess the microscopic effects of surface demineralization on human femoral allograft bone,
SEM was performed on NDB and DBW (Figure 1A). The result demonstrated that
demineralization markedly increases the porosity of the surface, as evidenced by the large
honeycomb space. To determine the effect of demineralization on rAAV-Luc coating
efficiency, the vector was applied to NDB and DBW in a 1% sorbitol solution containing red
food color and freeze-dried (Figure 1B-C). Quantitation of the surface coating revealed that
demineralization caused a significant 21.1 % (73.6 ± 3.9 % vs. 52.5 ± 2.6 %; p<0.001) increase
in surface area coating versus mineralized controls.
Effects of surface demineralization on rAAV-Luc transduction efficiency in vitro
In order to determine if the demineralization treatments had any effects on the rAAV vector,
we performed in vitro dose response and time course transduction experiments. For these
studies we chose to use the C3H10T1/2 cell line, since it is representative of the mesenchymal
progenitor cell targets of the gene therapy and has been demonstrated to mediate efficient bone
formation in vivo when transfected with osteogenic genes [22,23]. Figure 2A demonstrates the
significant increase in gene expression achieved by increasing the multiplicity of infection
(MOI) of soluble rAAV-Luc and the incubation period with cultures of C3H10T1/2 cells.
However, to directly test if the demineralization had any effects on rAAV-Luc transduction
in vitro C3H10T1/2 cells were incubated: i) alone, ii) with soluble rAAV-Luc, iii) with
uncoated DBW and soluble rAAV-Luc, or iv) with rAAV-Luc coated DBW, and assayed for
luciferase activity after 12hr, 24hr, 36hr, 48hr, 60hr, or 72hr (Figure 2B). The data demonstrated
that freeze-drying results in a delay in the peak gene expression from 12hr to 60hr, as would
be expected based on the rehydration and infection kinetics. However, no significant
differences were observed in the peak level of rAAV-Luc gene expression, demonstrating that
the demineralization process does not affect the net delivery of the vector.
Effects of surface demineralization on rAAV-Luc transduction efficiency in vivo
Based on the positive in vitro findings, we examined the effects of the demineralization process
on freeze-dried rAAV-Luc transduction in vivo via longitudinal BLI. First we evaluated the
dose dependent transduction efficiency following surgical implantation of rAAV-Luc coated
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DBW containing 107, 109 or 1010 particles (Figure 3). At the highest dose, significant transgene
expression could be detected on day 5, which peaked around day 10, and decreased to baseline
levels by day 21. Although less efficient, similar results were obtained with the lower titers
consistent with the predicted dose response. We also directly compared the in vivo transduction
efficiencies of rAAV-Luc coated NDB versus DBW (Figure 4). These results failed to
demonstrate any significant differences between the two groups, indicating that rAAV-coated
mineralized and demineralized cortical allografts have the same release kinetics and
transduction efficiencies in vivo.
Discussion
While the osteoconductive and biomechanical properties of cortical allografts make them
valuable for limb sparing surgery from segmental defects, their lack of osteoinductive and
osteogenic potential has led to poor long-term clinical results [3-5]. Thus, investigators have
been working towards developing tissue engineering approaches to overcome this limitation.
While addition of bone morphogenetic proteins (BMP) to cancellous allograft bone has proven
to be remarkably successful for cavitary bone defects [24], fracture healing [25], and spinal
fusion [26,27], the same is not true for large segmental defects that require exogenous BMP
activity for at least one week [22]. As a result, stem cell [28-31] and gene therapy [10,32-39]
approaches have been proposed as persistent osteogenic adjuvants for massive bone defects.
However, a major challenge for this tissue engineering approach is the generation of a
biomaterial that has both biomechanical properties required for structural grafting, and
absorptive properties required for retention of the therapeutic for in vivo delivery. While initial
attempts to utilize a biodegradable hydrophilic scaffold that can be wrapped around a cortical
allograft have demonstrated some potential [15-17], further work is required for them to
achieve clinical utility. Thus, we have proposed a less complicated approach to this problem,
which is to render the cortical surface more absorbent via demineralization. In so doing, we
have arrived at a clinically-relevant method that allows for uniform coating of soluble
osteogenic factors on the surface of the graft. However, future in vivo transduction experiments
are warranted to confirm the uniform distribution of the rAAV-coating.
A potentially important serendipitous find with these rAAV-coated allografts is the one week
delay in peak gene expression. By having the peak in target gene expression one week post-
op the gene therapy coincides with the end of the inflammatory phase, and initiation of the
reparative phase of bone healing [40]. Moreover, the waning of target gene expression at two
weeks may also be advantageous to allow timely commencement of the remodeling phase by
three weeks, and abate potential concerns about persistent unregulated gene therapy.
One major limitation of this study is that the quadriceps model, which was chosen based on
its facility to demonstrate in vivo transduction kinetics, does not simulate the bone defect model
in terms of its biomechanical stresses and decreased vascularity. Thus, future studies in the
femoral defect model will be useful to substantiate the clinical utility of surface demineralized
allografts for segmental defects.
Conclusions
We found that our clinically-relevant surface demineralization procedure significantly
increased the porosity and absorbency of human cortical bone allografts to allow for more
uniform coating of rAAV vectors. This procedure does so in a manner that does not affect
rAAV transduction efficiency or release kinetics from the allograft. Small and large animal
efficacy studies with demineralized structural allografts coated with freeze-dried rAAV
expressing angiogenic, osteogenic and/or osteoclastogenic genes are warranted to further
support the clinical utility of this approach.
Yazici et al. Page 5














This work was supported by unrestricted education grants from the Musculoskeletal Transplant Foundation, and
National Institutes of Health PHS awards HL51818, DK065988, EY005951, DE17096, AR46545, AR51469 and
AR54041.
References
1. Lord CF, Gebhardt MC, Tomford WW, Mankin HJ. Infection in bone allografts. Incidence, nature,
and treatment. J Bone Joint Surg Am 1988;70:369–376. [PubMed: 3279038]
2. Berrey BH Jr, Lord CF, Gebhardt MC, Mankin HJ. Fractures of allografts. Frequency, treatment, and
end-results. J Bone Joint Surg Am 1990;72:825–833. [PubMed: 2365716]
3. Enneking WF, Campanacci DA. Retrieved human allografts : a clinicopathological study. J Bone Joint
Surg Am 2001;83-A:971–986. [PubMed: 11451965]
4. Hornicek FJ, Gebhardt MC, Tomford WW, Sorger JI, Zavatta M, Menzner JP, et al. Factors affecting
nonunion of the allograft-host junction. Clin Orthop Relat Res 2001;382:87–98. [PubMed: 11154010]
5. Wheeler DL, Enneking WF. Allograft bone decreases in strength in vivo over time. Clin Orthop Relat
Res 2005;435:36–42. [PubMed: 15930919]
6. Ito H, Koefoed M, Tiyapatanaputi P, Gromov K, Goater JJ, Carmouche J, et al. Remodeling of cortical
bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. Nat Med 2005;11:291–
297. [PubMed: 15711561]
7. Koefoed M, Ito H, Gromov K, Reynolds DG, Awad HA, Rubery PT, et al. Biological Effects of rAAV-
caAlk2 Coating on Structural Allograft healing. Mol Ther 2005;12:212–218. [PubMed: 16043092]
8. Basile P, Dadali T, Jacobson J, Hasslund S, Ulrich-Vinther M, Soballe K, et al. Freeze-dried Tendon
Allografts as Tissue-engineering Scaffolds for Gdf5 Gene Delivery. Mol Ther 2008;16:466–473.
[PubMed: 18180771]
9. Sharif F, Hynes SO, McMahon J, Cooney R, Conroy S, Dockery P, et al. Gene-eluting stents:
comparison of adenoviral and adeno- associated viral gene delivery to the blood vessel wall in vivo.
Hum Gene Ther 2006;17:741–750. [PubMed: 16839273]
10. Awad HA, Zhang X, Reynolds DG, Guldberg RE, O’Keefe RJ, Schwarz EM. Recent advances in
gene delivery for structural bone allografts. Tissue Eng 2007;13:1973–1985. [PubMed: 17518728]
11. Corsi KA, Schwarz EM, Mooney DJ, Huard J. Regenerative medicine in orthopaedic surgery. J Orthop
Res 2007;25:1261–1268. [PubMed: 17551972]
12. Patel R, Trampuz A. Infections transmitted through musculoskeletal-tissue allografts. N Engl J Med
2004;350:2544–2546. [PubMed: 15201409]
13. Kwong FN, Ibrahim T, Power RA. Incidence of infection with the use of non-irradiated morcellised
allograft bone washed at the time of revision arthroplasty of the hip. J Bone Joint Surg Br
2005;87:1524–1526. [PubMed: 16260672]
14. Delloye C, Cornu O, Druez V, Barbier O. Bone allografts: What they can offer and what they cannot.
J Bone Joint Surg Br 2007;89:574–579. [PubMed: 17540738]
15. Bondre S, Lewandrowski KU, Hasirci V, Cattaneo MV, Gresser JD, Wise DL, et al. Biodegradable
foam coating of cortical allografts. Tissue Eng 2000;6:217–227. [PubMed: 10941216]
16. Lewandrowski KU, Bondre S, Hile DD, Thompson BM, Wise DL, Tomford WW, et al. Porous poly
(propylene fumarate) foam coating of orthotopic cortical bone grafts for improved osteoconduction.
Tissue Eng 2002;8:1017–1027. [PubMed: 12542947]
17. Schantz JT, Hutmacher DW, Lam CX, Brinkmann M, Wong KM, Lim TC, et al. Repair of calvarial
defects with customised tissue-engineered bone grafts II. Evaluation of cellular efficiency and
efficacy in vivo. Tissue Eng 2003;9 Suppl 1:S127–139. [PubMed: 14511476]
18. Childs LM, Goater JJ, O’Keefe RJ, Schwarz EM. Efficacy of etanercept for wear debris-induced
osteolysis. J Bone Miner Res 2001;16:338–347. [PubMed: 11204434]
19. Xiao X, Li J, Samulski RJ. Production of high-titer recombinant adeno-associated virus vectors in
the absence of helper adenovirus. J Virol 1998;72:2224–2232. [PubMed: 9499080]
20. Smith JS, Tian J, Muller J, Byrnes AP. Unexpected pulmonary uptake of adenovirus vectors in animals
with chronic liver disease. Gene Ther 2004;11:431–438. [PubMed: 14973536]
Yazici et al. Page 6













21. Thierry AR, Lunardi-Iskandar Y, Bryant JL, Rabinovich P, Gallo RC, Mahan LC. Systemic gene
therapy: biodistribution and long-term expression of a transgene in mice. Proc Natl Acad Sci U S A
1995;92:9742–9746. [PubMed: 7568209]
22. Moutsatsos IK, Turgeman G, Zhou S, Kurkalli BG, Pelled G, Tzur L, et al. Exogenously regulated
stem cell-mediated gene therapy for bone regeneration. Mol Ther 2001;3:449–461. [PubMed:
11319905]
23. Xie C, Reynolds D, Awad H, Rubery PT, Pelled G, Gazit D, et al. Structural bone allograft combined
with genetically engineered mesenchymal stem cells as a novel platform for bone tissue engineering.
Tissue Eng 2007;13:435–445. [PubMed: 17518596]
24. Bragdon CR, Doherty AM, Rubash HE, Jasty M, Li XJ, Seeherman H, et al. The efficacy of BMP-2
to induce bone ingrowth in a total hip replacement model. Clin Orthop Relat Res 2003:50–61.
[PubMed: 14646702]
25. Jones AL, Bucholz RW, Bosse MJ, Mirza SK, Lyon TR, Webb LX, et al. Recombinant human BMP-2
and allograft compared with autogenous bone graft for reconstruction of diaphyseal tibial fractures
with cortical defects. A randomized, controlled trial. J Bone Joint Surg Am 2006;88:1431–1441.
[PubMed: 16818967]
26. Boden SD, Zdeblick TA, Sandhu HS, Heim SE. The use of rhBMP-2 in interbody fusion cages.
Definitive evidence of osteoinduction in humans: a preliminary report. Spine 2000;25:376–381.
[PubMed: 10703113]
27. Burkus JK, Sandhu HS, Gornet MF, Longley MC. Use of rhBMP-2 in combination with structural
cortical allografts: clinical and radiographic outcomes in anterior lumbar spinal surgery. J Bone Joint
Surg Am 2005;87:1205–1212. [PubMed: 15930528]
28. Pelled G, T G, Aslan H, Gazit Z, Gazit D. Mesenchymal stem cells for bone gene therapy and tissue
engineering. Curr Pharm Des 2002;8:1917–1928. [PubMed: 12171527]
29. Dragoo JL, Choi JY, Lieberman JR, Huang J, Zuk PA, Zhang J, et al. Bone induction by BMP-2
transduced stem cells derived from human fat. J Orthop Res 2003;21:622–629. [PubMed: 12798061]
30. Arinzeh TL, Peter SJ, Archambault MP, van den Bos C, Gordon S, Kraus K, et al. Allogeneic
mesenchymal stem cells regenerate bone in a critical-sized canine segmental defect. J Bone Joint
Surg Am 2003;85-A:1927–1935. [PubMed: 14563800]
31. Usas A, Huard J. Muscle-derived stem cells for tissue engineering and regenerative therapy.
Biomaterials 2007;28:5401–5406. [PubMed: 17915311]
32. Lieberman JR, Daluiski A, Stevenson S, Wu L, McAllister P, Lee YP, et al. The effect of regional
gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of
segmental femoral defects in rats. J Bone Joint Surg Am 1999;81:905–917. [PubMed: 10428121]
33. Bonadio J, Smiley E, Patil P, Goldstein S. Localized, direct plasmid gene delivery in vivo: prolonged
therapy results in reproducible tissue regeneration. Nat Med 1999;5:753–759. [PubMed: 10395319]
[see comments]
34. Peng H, Wright V, Usas A, Gearhart B, Shen HC, Cummins J, et al. Synergistic enhancement of bone
formation and healing by stem cell-expressed VEGF and bone morphogenetic protein-4. J Clin Invest
2002;110:751–759. [PubMed: 12235106]
35. Southwood LL, Frisbie DD, Kawcak CE, Ghivizzani SC, Evans CH, McIlwraith CW. Evaluation of
Ad-BMP-2 for enhancing fracture healing in an infected defect fracture rabbit model. J Orthop Res
2004;22:66–72. [PubMed: 14656661]
36. Gafni Y, Pelled G, Zilberman Y, Turgeman G, Apparailly F, Yotvat H, et al. Gene therapy platform
for bone regeneration using an exogenously regulated, AAV-2-based gene expression system. Mol
Ther 2004;9:587–595. [PubMed: 15093189]
37. Evans CH, Ghivizzani SC, Herndon JH, Robbins PD. Gene therapy for the treatment of
musculoskeletal diseases. J Am Acad Orthop Surg 2005;13:230–242. [PubMed: 16112980]
38. Nixon AJ, Goodrich LR, Scimeca MS, Witte TH, Schnabel LV, Watts AE, et al. Gene therapy in
musculoskeletal repair. Ann N Y Acad Sci 2007;1117:310–327. [PubMed: 18056051]
39. Feeley BT, Conduah AH, Sugiyama O, Krenek L, Chen IS, Lieberman JR. In vivo molecular imaging
of adenoviral versus lentiviral gene therapy in two bone formation models. J Orthop Res
2006;24:1709–1721. [PubMed: 16788987]
Yazici et al. Page 7













40. Einhorn TA. The cell and molecular biology of fracture healing. Clin Orthop 1998:S7–21. [PubMed:
9917622]
Yazici et al. Page 8













Figure 1. Surface demineralization of cortical allograft bone increases its porosity and absorptive
distribution of rAAV-Luc
Scanning electron microscopy (SEM) images of non-demineralized bone (NDB) (left) and
demineralized cortical bone wafers (DBW) (right) prior to rAAV coating are shown at 3000
X magnification to demonstrate the marked increase in porosity of the demineralized bone
(A). 30μl of a 1% sorbitol solution of PBS with red food coloring containing 108 particles of
rAAV-Luc was pipetted onto a 10mm NDB (left) or DBW (right), and photographed before
(B) and after (C) freeze-drying. Note that the solution pools in the center of the mineralized
bone leading to poor coating after freeze-drying, while the solution is more evenly distributed
on the demineralized bone leading to a significant increase in surface coating after freeze-
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drying (52.5 ± 2.6 % vs. 73.6 ± 3.9 %; p<0.001). Further evidence of improved rAAV-coating
uniformity is provided by 9 X SEM images of the freeze-dried wafers (D) in which the border
of the rAAV coating is clearly visible on the NDB (arrows), while the even distribution on the
DBW renders this boarder more transparent.
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Figure 2. Surface demineralization does not alter rAAV release kinetics and transduction efficiency
in vitro
The in vitro transduction efficiency of the rAAV-Luc vector was determined by infecting a
monolayer C3H10T1/2 (105 cells per well) at the indicated multiplicity of infection (MOI) and
assaying the cells for luciferase activity (relative light units, RLU) at 12hr or 24hr. All
transduction conditions lead to a significant increase in RLU versus the uninfected control
(asterisk indicates p<0.05) (A). The effects of the demineralized bone wafer (DBW) on rAAV
transduction and freeze-dried rAAV-Luc release kinetics were determined in C3H10T1/2
transduction experiments in vitro (B). Cells were incubated: alone (white bars), with soluble
rAAV-Luc (MOI = 100) only (light gray bars), with uncoated DBW and soluble rAAV-Luc
(MOI = 100) (dark gray bars), or with rAAV-Luc (MOI = 100) coated-DBW (black bars). RLU
assays were performed at the indicated time following treatment. The peak transduction time
is indicated by the significant increase over the 12hr control for each group (*; p<0.05). No
significant effects of the DBW were observed on soluble rAAV-Luc transduction (p>0.05).
However, the peak of soluble rAAV-Luc transduction occurred at 12hr with or without DBW,
while the peak of freeze-dried rAAV transduction occurred at 60hr, but the RLU values of
these peaks in the DBW containing cultures were not significantly different (p>0.05).
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Figure 3. In vivo transduction of rAAV-Luc coated demineralized bone wafers
Demineralized bone wafers (DBW) were coated with 107, 109, or 1010 particles of rAAV-Luc
as described in Figure 1, surgically implanted into the right quadriceps of mice (n=6), and
temporal bioluminescent imaging (BLI) was performed at days 1, 3, 5, 7, 10, 14, 21. A
longitudinal series of BLI photographs of the experimental leg from a representative mouse in
each is shown at the indicated time (A). The mean BLI ± SD for each dose of rAAV-Luc
determined at each time point is presented on a log-scale vertical axis (B). + indicates a
significant increase in peak intensity on Day 10 vs. Day 1 for both the 109 and 1010 groups
(p<0.001). # indicates significant differences in BLI for the 1010 group versus the 107 group
(p<0.01) at the indicated time point. * indicates significant differences in BLI for the 1010
group versus the 109 group at the indicated time point (p<0.05).
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Figure 4. Demineralization of cortical allograft bone does not affect the rAAV-coating release
kinetics
Non-demineralized bone (NDB) and demineralized bone wafers (DBW) were coated with
1010 rAAV-Luc particles and surgically implanted into mice (n=5) as described in Figure 4.
Longitudinal BLI images of a representative mouse from each are shown (A). The BLI signal
on days 1, 3, 5, 7, 10, 14, 21, and 28 of each mouse is presented (B). No significant differences
in the BLI signal could be observed between the two groups at any time point (p>0.05). Note
that the peak BLI for both groups occurs on day 7 with no significant changes between day 7
and 14 for either group (p>0.05), but drops to levels below Day 1 by Day 28 for both groups.
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